Lanx has announced the initial launch of the ALTA stand-alone anterior cervical discectomy and fusion (ACDF) system and the system will be showcased at the 29th annual meeting of the American Association of Neurosurgeons/Congress of Neurosurgeons (AANS/CNS) Section on Disorders of the Spine and Peripheral Nerves (6-9 March 2013, Phoenix, USA).
According to a company press release, the system is the first to feature three low-profile plate options and will be showcased at booth number 208 at the AANS/CNS conference.
“The ALTA System is the first to offer surgeons true versatility in the operating room through its modular plates and various screw angles, designed to meet the anatomic needs of each patient. Its addition to our cervical fusion portfolio supports our continued focus on reducing invasiveness, optimizing safety, and increasing overall efficiency in spine surgery,” said Dan Gladney, chief executive officer, Lanx.
The ALTA System is a stand-alone integrated plate and interbody system intended for the treatment of degenerative disc disease in the cervical spine. It includes modular zero-profile and low-profile plate options to support a range of patient anatomies for improved intraoperative flexibility. The zero-plate is designed for use with two lag screws, while the half-and full-plates accommodate three and four lag screws, respectively, for additional stability.
John E. Wanebo, neurosurgeon at Barrow Neurosurgical Associates in Phoenix, USA, said, “The ALTA System is a novel modular cage-plate device for the cervical spine, with an evolved design to maximise ease of use for the surgeon. The full-plate option has been quite effective in trauma cases, while the half-plate applies well to the ends of the cervical spine. In my experience, the small footprint and low-profile of each plate option also reduce the amount of dissection necessary and help decrease the invasiveness of the procedure.”
The ALTA System features smooth, secure screw locking caps for patient comfort, and the PEEK interbody is available in multiple large footprints with increased graft volume. The System’s compact instrumentation and device size also enable reduced tissue retraction for a less invasive implantation. ALTA is expected to be fully commercialised in the USA this autumn.
